Abstract:Importance: Menopausal hormone therapy (MHT) is the treatment of choice for symptoms of menopause. However, its adoption is hindered by the risk-benefit trade-off in relation to acute and chronic diseases. Objective: To evaluate trends in and correlates of MHT use among postmenopausal women in the US from 1999 to March 2020. Design, setting, and participants: This serial cross-sectional analysis of MHT use used data from the nationally representative National Health and Nutrition Examination Survey (NHANES). Participants included noninstitutionalized US postmenopausal women from 10 NHANES study cycles (1999-2000 to 2017-March 2020 [pre-COVID-19 pandemic]). Data were analyzed from December 2023 to April 2024. Exposures: NHANES study cycle. Main outcomes and measures: Prevalence of MHT use was extracted from the prescription medication data collected during NHANES household interviews. MHT formulations were determined by hormone type. Results: Data on 13 048 US postmenopausal women (47.1% ≥65 years old) were analyzed. From 1999 to 2020, the prevalence of MHT use decreased among women of all age groups, from 26.9% (95% CI, 22.6%-31.7%) in 1999 to 4.7% (95% CI, 3.4%-6.5%) in 2020. Until 2002, MHT use was highest among women aged 52 to 65 years, but since 2005, MHT use has been highest among women younger than 52 years. MHT use decreased by 23.5% (95% CI, 11.4%-35.6%), 31.4% (95% CI, 23.4%-39.5%), and 10.6% (95% CI, 6.3%-14.8%) for women younger than 52 years, 52 years to younger than 65 years, and 65 years and older, respectively. Prevalence of MHT use decreased from 13.8% (95% CI, 8.5%-21.7%) to 2.6% (95% CI, 1.5%-4.6%) for Hispanic women, 11.9% (95% CI, 8.5%-16.3%) to 0.5% (95% CI, 0.2%-1.1%) for non-Hispanic Black women, and 31.4% (95% CI, 27.1%-36.1%) to 5.8% (95% CI, 4.1%-8.2%) for non-Hispanic White women. Non-Hispanic White women consistently had the highest prevalence of MHT use. Estrogen-only formulation accounted for more than 50% of the MHT for most study periods. The prevalence of MHT use varied by family income-to-poverty ratio, health insurance coverage in all racial and ethnic groups, weight, and smoking status among non-Hispanic White women, as well as by education attainment among non-Hispanic Black and Hispanic women. Conclusions and relevance: Results of this cross-sectional study show that over the past 2 decades, MHT use declined among US postmenopausal women of all age and racial and ethnic groups. Women of racial and ethnic minority groups had lower prevalence of MHT use compared to non-Hispanic White women.

Menopausal hormone therapy decreases the likelihood of diabetes development in peri‐menopausal individuals with prediabetes

Risk of Stroke in Healthy Postmenopausal Women During and after Hormone Therapy: a Meta-Analysis.

Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review

Change in Metabolic Parameters and Reproductive Hormones from Baseline to 6-Month Hormone Therapy

Menopausal Hormone Therapy Use Among Postmenopausal Women

Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders

Relationship between menopausal hormone therapy and breast cancer: A nationwide population‐based cohort study

Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women

Menopausal Status, Age at Natural Menopause and Risk of Diabetes in China: a 10-Year Prospective Study of 300,000 Women

Prior pre-eclampsia does not diminish the vascular protective effect of menopausal hormone therapy

Sex Differences in 'Life's Essential 8' cardiovascular health and Type 2 Diabetes Mellitus Risk Across Menopause Stages

Association between menopausal hormone therapy and the risk of gastric cancer: A Korean nationwide population-based cohort study

Longitudinal Changes in Sex Hormone Binding Globulin (SHBG) and Risk of Incident Diabetes: The Study of Women’s Health Across the Nation (SWAN)

Prevention of Postmenopausal Osteoporosis in Chinese Women: a 5-Year, Double-Blind, Randomized, Parallel Placebo-Controlled Study

Association of age at menopause with type 2 diabetes mellitus in postmenopausal women in the United States: National Health and Nutrition Examination Survey 2011–2018

Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study

Association between Reproductive Factors and Type 2 Diabetes: A Cross-Sectional Study

Clinical observation of menopause hormone therapy in postmenopausal women with euthyroid and mild subclinical hypothyroidism

Level of hormones in menopause in relation to diabetic retinopathy among type 2 diabetic women

Update on hormone therapy for the management of postmenopausal women

Correction: Clinical Observation of Menopause Hormone Therapy in Postmenopausal Women with Euthyroid and Mild Subclinical Hypothyroidism.